Universität zu Köln

Journal Article

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Chyla, Brenda, Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Puvvada, Soham, Wendtner, Clemens, Davids, Matthew S., Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Wierda, William and Hallek, Michael (2017). Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. Leuk. Lymphoma, 58. S. 234 - 236. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny and Mobasher, Mehrdad (2018). High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kater, Arnon P., Eichhorst, Barbara, Owen, Carolyn, Jaeger, Ulrich, Chyla, Brenda, Lefebure, Marcus, Millen, Rosemary, Jiang, Yanwen, Thadani-Mulero, Maria and Seymour, John F. (2022). Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 140. S. 7010 - 7013. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kater, Arnon P., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Kipps, Thomas J., Owen, Carolyn, Boyer, Michelle, Humphrey, Kathryn, Punnoose, Elizabeth A., Wang, Jue, Chyla, Brenda, Verdugo, Maria E., Wu, Jenny, Jiang, Yanwen, Mobasher, Mehrdad and Seymour, John F. (2018). First Prospective Data on Impact of Minimal Residual Disease on Long - Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter ORCID: 0000-0001-5617-4403, D'Rozario, James, Assouline, Sarit ORCID: 0000-0002-7638-1589, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn and Seymour, John F. (2020). Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J. Clin. Oncol., 38 (34). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G. and Seymour, John F. (2019). Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood, 134 (2). S. 111 - 123. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roberts, Andrew W., Seymour, John F., Eichhorst, Barbara, Stilgenbauer, Stephan, Choi, Michael Y., Davids, Matthew S., Gerecitano, John F., Popovic, Relja, Chyla, Brenda, Zhu, Ming, Verdugo, Maria, Potluri, Jalaja, Lash, Leanne, Kim, Su Young and Hallek, Michael (2016). Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz ORCID: 0000-0002-3411-6357, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle and Kater, Arnon P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140 (8). S. 839 - 851. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Desai, Monali, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod, Gordon, Gary, Hallek, Michael and Wierda, William G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol., 17 (6). S. 768 - 779. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Hillmen, Peter, Seymour, John F., Coutre, Steven, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Schuh, Anna, Assouline, Sarit, Wendtner, Clemens-Martin, Roberts, Andrew W., Davids, Matthew S., Bloehdorn, Johannes, Munir, Talha, Boettcher, Sebastian, Zhou, Lang, Salem, Ahmed Hamed, Desai, Monali, Chyla, Brenda, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Gordon, Gary, Hallek, Michael and Wierda, William G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol., 36 (19). S. 1973 - 1984. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Stilgenbauer, Stephan, Eichhorst, Barbara F., Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech, Mulligan, Stephen, Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod A., Gordon, Gary, Hallek, Michael and Wierda, William (2015). Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Wierda, William, Chyla, Brenda, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Wendtner, Clemens-Martin, Davids, Matthew, Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Stilgenbauer, Stephan and Hallek, Michael (2017). Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial. Clin. Lymphoma Myeloma Leuk., 17. S. S303 - 1. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Wierda, William G., Kipps, Thomas J., Al-Sawaf, Othman, Chyla, Brenda, Biondo, Juliana M. L., Mun, Yong, Jiang, Yanwen and Seymour, John F. (2022). Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk. Lymphoma, 63 (12). S. 2765 - 2785. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403